Home » USA Broker Ratings » Humana Inc. – Consensus Indicates Potential 7.1% Upside

Humana Inc. – Consensus Indicates Potential 7.1% Upside

Humana Inc. with ticker code (HUM) now have 22 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 500 and 345 calculating the average target price we see 422.41. With the stocks previous close at 394.43 this is indicating there is a potential upside of 7.1%. There is a 50 day moving average of 372.83 and the 200 moving average now moves to 347.87. The company has a market cap of $52,498m. Company Website: http://www.humana.com

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; financial protection products; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE South Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2019, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Join us on our new LinkedIn page

Follow us on LinkedIn